{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"PETV","limit":50},"count":50,"signals":[{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":35,"context":"and sale of medical devices are subject to future change. We cannot predict what impact, if any, those changes might have on our business. Failure to comply with regulatory requirements could have a material adverse effect on our business, financial condition, and results of operations. Pertaining to our Spryng product (offered for veterinary use only), in the U.S., the FDA does not require submission of a 510(k), PMA,","filed_date":"2025-07-10","accession":"0001641172-25-018617","full_text":"https://origin.rootz.global/static/filing/0001641172-25-018617.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":19,"context":"to provide, among other things, a compensation discussion and analysis or a compensation committee report, and certain other tabular and narrative disclosures relating to executive compensation. Our named executive officers (Named Executive Officers or NEOs) for fiscal year ended March 31, 2025 (fiscal 2025) were as follows: |  | John Lai, our Chief Executive Officer and President; | | |  | Garry Lowenthal, our Chief F","filed_date":"2025-07-10","accession":"0001641172-25-018617","full_text":"https://origin.rootz.global/static/filing/0001641172-25-018617.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":16,"context":"to provide, among other things, a compensation discussion and analysis or a compensation committee report, and certain other tabular and narrative disclosures relating to executive compensation. Our named executive officers (Named Executive Officers or NEOs) for fiscal year ended March 31, 2024 (fiscal 2024) were as follows: |  | John Lai, our Chief Executive Officer and President; | | |  | Garry Lowenthal, our Chief F","filed_date":"2024-07-09","accession":"0001493152-24-026619","full_text":"https://origin.rootz.global/static/filing/0001493152-24-026619.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":35,"context":"e. We cannot predict what impact, if any, those changes might have on our business. If we begin selling our products internationally, failure to comply with these regulatory requirements could have a material adverse effect on our business, financial condition, and results of operations. | 12 | | **Research and Development** **** The Company is currently pursuing advancements in the composition, methods of manufacture a","filed_date":"2024-06-28","accession":"0001493152-24-025637","full_text":"https://origin.rootz.global/static/filing/0001493152-24-025637.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":20,"context":"to provide, among other things, a compensation discussion and analysis or a compensation committee report, and certain other tabular and narrative disclosures relating to executive compensation. Our named executive officers (Named Executive Officers or NEOs) for fiscal year ended March 31, 2024 (fiscal 2024) were as follows: |  | John Lai, our Chief Executive Officer and President; | | |  | Garry Lowenthal, our Chief F","filed_date":"2024-06-28","accession":"0001493152-24-025637","full_text":"https://origin.rootz.global/static/filing/0001493152-24-025637.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":23,"context":"to provide, among other things, a compensation discussion and analysis or a compensation committee report, and certain other tabular and narrative disclosures relating to executive compensation. Our named executive officers (Named Executive Officers or NEOs) for fiscal year ended March 31, 2023 (fiscal 2023) were as follows: |  |  |  John Lai, Chief Executive Officer and President; | | |  |  |  | | |  |  |  Robert J. F","filed_date":"2023-10-03","accession":"0001493152-23-035225","full_text":"https://origin.rootz.global/static/filing/0001493152-23-035225.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":31,"context":"d in the Registration Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect or would reasonably be expected to have a material adverse effect on or affecting the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders e","filed_date":"2023-08-24","accession":"0001493152-23-030040","full_text":"https://origin.rootz.global/static/filing/0001493152-23-030040.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":23,"context":"to provide, among other things, a compensation discussion and analysis or a compensation committee report, and certain other tabular and narrative disclosures relating to executive compensation. Our named executive officers (Named Executive Officers or NEOs) for fiscal year ended March 31, 2023 (fiscal 2023) were as follows: |  |  |  John Lai, our Chief Executive Officer and President; | | |  |  |  Robert Folkes, our C","filed_date":"2023-06-29","accession":"0001493152-23-022907","full_text":"https://origin.rootz.global/static/filing/0001493152-23-022907.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":19,"context":"to provide, among other things, a compensation discussion and analysis or a compensation committee report, and certain other tabular and narrative disclosures relating to executive compensation. Our named executive officers (Named Executive Officers) for the fiscal year ended March 31, 2022 (fiscal 2022) were as follows: |  |  |  John Lai, Chief Executive Officer and President; | | |  |  |  Robert J. Folkes, Chief Fina","filed_date":"2022-08-26","accession":"0001493152-22-024156","full_text":"https://origin.rootz.global/static/filing/0001493152-22-024156.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":18,"context":"to provide, among other things, a compensation discussion and analysis or a compensation committee report, and certain other tabular and narrative disclosures relating to executive compensation. Our named executive officers (Named Executive Officers or NEOs) for fiscal year ended March 31, 2022 (fiscal 2022) were as follows: |  |  |  John Lai, our Chief Executive Officer and President; | | |  |  |  Robert Folkes, our C","filed_date":"2022-06-24","accession":"0001493152-22-017738","full_text":"https://origin.rootz.global/static/filing/0001493152-22-017738.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":14,"context":"to provide, among other things, a compensation discussion and analysis or a compensation committee report, and certain other tabular and narrative disclosures relating to executive compensation. Our named executive officers (Named Executive Officers or NEOs) for fiscal year ended March 31, 2022 (fiscal 2022) were as follows: John Lai, our Chief Executive Officer and President; Robert Folkes, our Chief Financial Officer","filed_date":"2022-05-05","accession":"0001493152-22-012194","full_text":"https://origin.rootz.global/static/filing/0001493152-22-012194.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":15,"context":"surance Dimensions, Inc., as our independent registered public accountants for the fiscal year ending March 31, 2022; | | |  | 3. | To approve, on a nonbinding advisory basis, the compensation of our named executive officers; | | |  | 4. | To vote, on a nonbinding advisory basis, on the preferred frequency of holding an advisory vote on executive compensation; | | |  | 5. | To transact such other business that may prope","filed_date":"2022-01-18","accession":"0001493152-22-001485","full_text":"https://origin.rootz.global/static/filing/0001493152-22-001485.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":15,"context":"0 of costs capitalized to intangible assets. We used $65,196 and $103,807 of net cash in investing activities in fiscal 2020 and 2019, respectively. Our use in fiscal 2020 consisting primarily of the purchase of equipment for $32,791 and an increase of patents and trademarks for $43,386, which were offset by proceeds from the sale of equipment in the amount of $12,481. ** ** **Net Cash Provided by Financing Activities** Dur","filed_date":"2020-10-13","accession":"0001493152-20-019321","full_text":"https://origin.rootz.global/static/filing/0001493152-20-019321.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":18,"context":"Date shall have the meaning ascribed to such term in Section 4.1(c). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(m). Maximum Rate shall have the meaning ascribed to such t","filed_date":"2020-06-18","accession":"0001493152-20-011354","full_text":"https://origin.rootz.global/static/filing/0001493152-20-011354.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":13,"context":"ur shareholders and Gel-Del shareholders. Shareholder approval of this merger was obtained from shareholders of Gel-Del in March 2015 and from our shareholders in April 2015, and concurrently we also appointed the directors of Gel-Del to our Board of Directors. We then controlled Gel-Del, combined all Gel-Del operations with ours, and were responsible to provide future funding for Gel-Del. Accordingly, we concluded tha","filed_date":"2018-08-13","accession":"0001493152-18-011562","full_text":"https://origin.rootz.global/static/filing/0001493152-18-011562.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":14,"context":"creating one combined entity utilizing Gel-Del technology to produce, market, and sell medical products based on Gel-Del technology for both animals and humans. After lengthy negotiations the parties entered into a definitive agreement for this merger, which resulted in the consummation of the merger in April, 2017. | 4 | | ** ** **CURRENT BUSINESS OPERATIONS** **General** |  |  |  We are an emerging biomedical device company focus","filed_date":"2017-12-13","accession":"0001493152-17-014555","full_text":"https://origin.rootz.global/static/filing/0001493152-17-014555.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":6,"context":"ined entity utilizing Gel-Del technology to produce, market and sell medical products based on Gel-Del technology for both animals and humans. After lengthy negotiations during 2014, the parties have entered into a definitive agreement for this merger. **INFORMATION STATEMENTS** **April 22, 2015 Information Statement** On April 10, 2015, our Board of Directors and majority shareholders, believing it to be in our best interests and","filed_date":"2016-03-23","accession":"0001477932-16-009141","full_text":"https://origin.rootz.global/static/filing/0001477932-16-009141.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":35,"context":"conducted, other than such franchises, licenses, permits, authorizations and approvals the lack of which, individually or in the aggregate, has not had and would not reasonably be expected to have a material adverse effect on PetVivo, a material adverse effect on the ability of PetVivo to perform its obligations under this Agreement or on the ability of PetVivo to consummate the Transactions (a PetVivo Material Adverse","filed_date":"2014-03-13","accession":"0001477932-14-001042","full_text":"https://origin.rootz.global/static/filing/0001477932-14-001042.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":98,"match_count":11,"context":"10,000 shares to key employees as incentive grants, fully vested, and exercisable over a five-year term at $1.00/share valued at $187,000; v) warrants for 1,500,000 shares to accredited investors who purchased units at $.35/unit in a private placement that were comprised of 1 share of common stock and 1 warrant for purchase of common stock, fully vested, and exercisable over a three-year term at $0.50/share; vi) warr","filed_date":"2019-07-31","accession":"0001493152-19-011411","full_text":"https://origin.rootz.global/static/filing/0001493152-19-011411.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":95,"match_count":10,"context":"corporate law are material factors which demonstrate his qualifications to serve on our Board of Directors. **David B. Masters, Ph.D.** Dr. Masters has served as a director since April 2015, and was appointed to serve as our Director of Science and Technology effective as of September 1, 2020. From April 2015 to December 2017, he served as our Chief Technical Officer. Dr. Masters is the founder of and served as Chief Executive Of","filed_date":"2021-07-13","accession":"0001493152-21-016741","full_text":"https://origin.rootz.global/static/filing/0001493152-21-016741.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":85,"match_count":5,"context":"tive March 18, 2014; and (ii) Ghislaine St.-Hilaire as the President/Chief Executive Officer and as a member of the Board of Directors effective March 19, 2014. Simultaneously, the Board of Directors appointed John Lai as the President/Chief Executive Officer and member of the Board of Directors and John F. Dolan as the Secretary, Treasurer/Chief Financial Officer and a member of the Board of Directors. Therefore, our directors and","filed_date":"2014-07-14","accession":"0001477932-14-003636","full_text":"https://origin.rootz.global/static/filing/0001477932-14-003636.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":82,"match_count":4,"context":"the Sarbanes-Oxley Act, and failure to achieve and maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act, when applicable, could have a material adverse effect on our business and share price.** As an emerging growth company, we are not required to evaluate our internal control over financial reporting in a manner that meets the standards of publicly-traded","filed_date":"2017-12-13","accession":"0001493152-17-014555","full_text":"https://origin.rootz.global/static/filing/0001493152-17-014555.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":82,"match_count":4,"context":"the Sarbanes-Oxley Act, and failure to achieve and maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act, when applicable, could have a material adverse effect on our business and share price.** As an emerging growth company, we are not required to evaluate our internal control over financial reporting in a manner that meets the standards of publicly-traded","filed_date":"2016-08-17","accession":"0001477932-16-012044","full_text":"https://origin.rootz.global/static/filing/0001477932-16-012044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":82,"match_count":4,"context":"the Sarbanes-Oxley Act, and failure to achieve and maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act, when applicable, could have a material adverse effect on our business and share price.** As an emerging growth company, we are not required to evaluate our internal control over financial reporting in a manner that meets the standards of publicly-traded","filed_date":"2016-03-23","accession":"0001477932-16-009141","full_text":"https://origin.rootz.global/static/filing/0001477932-16-009141.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":82,"match_count":4,"context":"the Sarbanes-Oxley Act, and failure to achieve and maintain effective internal control over financial reporting in accordance with Section404 of the Sarbanes-Oxley Act, when applicable, could have a material adverse effect on our business and share price. As an emerging growth company, we are not required to evaluate our internal control over financial reporting in a manner that meets the standards of publicly-traded c","filed_date":"2014-07-14","accession":"0001477932-14-003636","full_text":"https://origin.rootz.global/static/filing/0001477932-14-003636.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"counting and financial, and legal and compliance functions, new product development efforts, research and development data, communications, supply chain and product distribution, order entry and fulfillment, and other business processes. Any material failure of our information technology systems to perform satisfactorily, or their damage or interruption from circumstances beyond our control such as p","filed_date":"2022-06-24","accession":"0001493152-22-017738","full_text":"https://origin.rootz.global/static/filing/0001493152-22-017738.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":80,"match_count":5,"context":"ined entity utilizing Gel-Del technology to produce, market and sell medical products based on Gel-Del technology for both animals and humans. After lengthy negotiations during 2014, the parties have entered into a definitive agreement for this merger. **INFORMATION STATEMENT** On April 10, 2015, our Board of Directors and majority shareholders, believing it to be in our best interests and of our shareholders: (i) approved the clos","filed_date":"2016-08-17","accession":"0001477932-16-012044","full_text":"https://origin.rootz.global/static/filing/0001477932-16-012044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":80,"match_count":10,"context":"ssets and to conduct their businesses as presently conducted, other than such franchises, licenses, permits, authorizations and approvals the lack of which, would not reasonably be expected to have a material adverse effect on Gel-Del or its ability to perform its obligations under this Agreement. Gel-Del is duly qualified to do business in each jurisdiction where the nature of its business or its ownership or leasing o","filed_date":"2014-11-21","accession":"0001477932-14-006639","full_text":"https://origin.rootz.global/static/filing/0001477932-14-006639.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":79,"match_count":8,"context":"corporate law are material factors which demonstrate his qualifications to serve on our Board of Directors. **David B. Masters, Ph.D.** Dr. Masters has served as a director since April 2015, and was appointed to serve as our Director of Science and Technology effective as of September 1, 2020. From April 2015 to December 2017, he served as our Chief Technical Officer. Dr. Masters is the founder of and served as Chief Executive Of","filed_date":"2021-06-29","accession":"0001493152-21-015435","full_text":"https://origin.rootz.global/static/filing/0001493152-21-015435.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":72,"match_count":4,"context":"mbine the two companies into one business entity producing, marketing and selling medical products based on Gel-Del technology for both humans and animals. **License Agreement** On August 2, 2013, we entered into a licensing agreement with Gel-Del (the \"License Agreement\"), pursuant to which Gel-Del intended to engage in the manufacture and supply of products derived from technology, including protein based biomaterials and device","filed_date":"2017-10-16","accession":"0001477932-17-005055","full_text":"https://origin.rootz.global/static/filing/0001477932-17-005055.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":59,"match_count":3,"context":"ined entity utilizing Gel-Del technology to produce, market and sell medical products based on Gel-Del technology for both animals and humans. After lengthy negotiations during 2014, the parties have entered into a definitive agreement for this merger. **CURRENT BUSINESS OPERATIONS** We are an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for pets, b","filed_date":"2017-09-18","accession":"0001477932-17-004540","full_text":"https://origin.rootz.global/static/filing/0001477932-17-004540.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":58,"match_count":6,"context":"-Del shareholders was obtained through a meeting of its shareholders duly held on March 25, 2015 pursuant to Minnesota corporate statutes. Concurrent with obtaining full shareholder approval, we also appointed the directors of Gel-Del as directors of our company. | 14 | | | | | We then controlled Gel-Del, combined all Gel-Del operations with ours, and became responsible to provide future funding for Gel-Del. Accordingl","filed_date":"2019-02-14","accession":"0001493152-19-002082","full_text":"https://origin.rootz.global/static/filing/0001493152-19-002082.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":57,"match_count":4,"context":"ctors of the Registrant to conclude that Mr. Pomerleau should serve as director of the Registrant. In accordance with the terms and provisions of the Letter of Intent with iSpeedzone, Danny Gagne was appointed as an Executive Vice President effective October 10, 2012. In accordance with the terms and provisions of the Rescission Agreement, Mr. Gagne resigned effective April 12, 2013. All directors hold office until the completion of the","filed_date":"2013-07-15","accession":"0001477932-13-003209","full_text":"https://origin.rootz.global/static/filing/0001477932-13-003209.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"the NASDAQ Capital Market. The Named Executive Officers received the following RSU grants: Mr. Lai - 150,000 RSUs, Mr. Folkes - 54,000 RSUs, and Mr. Meyer - 65,000 RSUs. These RSUs vest in three installments, with 1/3 vesting on March 31, 2022, 1/3 vesting on March 31, 2023 and 1/3 vesting on March 31, 2024, based upon continued employment with the Company. These RSUs will vest immediately if there i","filed_date":"2022-08-26","accession":"0001493152-22-024156","full_text":"https://origin.rootz.global/static/filing/0001493152-22-024156.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"counting and financial, and legal and compliance functions, new product development efforts, research and development data, communications, supply chain and product distribution, order entry and fulfillment, and other business processes. Any material failure of our information technology systems to perform satisfactorily, or their damage or interruption from circumstances beyond our control such as p","filed_date":"2021-07-13","accession":"0001493152-21-016741","full_text":"https://origin.rootz.global/static/filing/0001493152-21-016741.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":55,"match_count":5,"context":"| | |  and Former Director | |  | 2019 | | |  | 67,355 | | |  | 0 | | |  | (177,600 | ) | |  | 0 | | |  | 0 | | |  | (110,245 | ) | | **OUTSTANDING EQUITY AWARDS** As of March 31, 2020, the following named executive officers had the following unexercised options or warrants, stock that has not vested, and equity incentive plan awards: John Lai has warrants for 1,223,740 common shares; John Carruth has warrants for 657,0","filed_date":"2020-06-29","accession":"0001493152-20-012125","full_text":"https://origin.rootz.global/static/filing/0001493152-20-012125.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":53,"match_count":6,"context":"-Del shareholders was obtained through a meeting of its shareholders duly held on March 25, 2015 pursuant to Minnesota corporate statutes. Concurrent with obtaining full shareholder approval, we also appointed the directors of Gel-Del as directors of our company. | | 14 | | | | | | We then controlled Gel-Del, combined all Gel-Del operations with ours, and became responsible to provide future funding for Gel-Del. Accord","filed_date":"2018-11-14","accession":"0001493152-18-016027","full_text":"https://origin.rootz.global/static/filing/0001493152-18-016027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":53,"match_count":6,"context":"-Del shareholders was obtained through a meeting of its shareholders duly held on March 25, 2015 pursuant to Minnesota corporate statutes. Concurrent with obtaining full shareholder approval, we also appointed the directors of Gel-Del as directors of our company. We then controlled Gel-Del, combined all Gel-Del operations with ours, and became responsible to provide future funding for Gel-Del. Accordingly, we concluded","filed_date":"2018-08-24","accession":"0001493152-18-012573","full_text":"https://origin.rootz.global/static/filing/0001493152-18-012573.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":51,"match_count":2,"context":"and sale of medical devices are subject to future change. We cannot predict what impact, if any, those changes might have on our business. Failure to comply with regulatory requirements could have a material adverse effect on our business, financial condition and results of operations. Exported devices are subject to the regulatory requirements of each country to which the device is exported. Some countries do not have","filed_date":"2021-07-13","accession":"0001493152-21-016741","full_text":"https://origin.rootz.global/static/filing/0001493152-21-016741.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":51,"match_count":2,"context":"insurance on acceptable terms. Moreover, insurance may not provide adequate coverage against potential liabilities. As a result, product liability claims, even if successfully defended, could have a material adverse effect on our business, financial condition and results of operations. The commercial success of the Proteina21 products will depend upon the degree of market acceptance by consumers. If the Proteina21 prod","filed_date":"2013-07-15","accession":"0001477932-13-003209","full_text":"https://origin.rootz.global/static/filing/0001477932-13-003209.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":50,"match_count":5,"context":"174 and $3,826, respectively. During the three months ended June 30, 2019, we recorded a gain on sale of asset in the amount of $450 wherein we sold an asset that was fully depreciated and originally purchased for $1,004 for $450. ** ** **NOTE 7 INTANGIBLE ASSETS** The components of intangible assets, all of which are finite-lived, were as follows: |  | |  September 30, 2019 | | |  March 31, 2019 | | | |  Patent","filed_date":"2019-11-19","accession":"0001493152-19-018021","full_text":"https://origin.rootz.global/static/filing/0001493152-19-018021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":49,"match_count":3,"context":"e. We cannot predict what impact, if any, those changes might have on our business. If we begin selling our products internationally, failure to comply with these regulatory requirements could have a material adverse effect on our business, financial condition, and results of operations. **Research and Development** **** The Company is currently pursuing advancements in the composition methods of manufacture and use for","filed_date":"2023-06-29","accession":"0001493152-23-022907","full_text":"https://origin.rootz.global/static/filing/0001493152-23-022907.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"counting and financial, and legal and compliance functions, new product development efforts, research and development data, communications, supply chain and product distribution, order entry and fulfillment, and other business processes. Any material failure of our information technology systems to perform satisfactorily, or their damage or interruption from circumstances beyond our control such as p","filed_date":"2025-07-10","accession":"0001641172-25-018617","full_text":"https://origin.rootz.global/static/filing/0001641172-25-018617.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"counting and financial, and legal and compliance functions, new product development efforts, research and development data, communications, supply chain and product distribution, order entry and fulfillment, and other business processes. Any material failure of our information technology systems to perform satisfactorily, or their damage or interruption from circumstances beyond our control such as p","filed_date":"2024-06-28","accession":"0001493152-24-025637","full_text":"https://origin.rootz.global/static/filing/0001493152-24-025637.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"counting and financial, and legal and compliance functions, new product development efforts, research and development data, communications, supply chain and product distribution, order entry and fulfillment, and other business processes. Any material failure of our information technology systems to perform satisfactorily, or their damage or interruption from circumstances beyond our control such as p","filed_date":"2021-06-29","accession":"0001493152-21-015435","full_text":"https://origin.rootz.global/static/filing/0001493152-21-015435.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"any has applied for forgiveness. The loan accrues interest at a rate of 1% per annum and matures on May 1, 2022; if not forgiven prior to December 1, 2020, the Company is required to pay monthly installments toward principal and interest until the note is paid in full. ** ** **NOTE 13 ACCRUED EXPENSES RELATED PARTY** At September 30, 2020, the Company is obligated to pay $21,270 in accrued expenses d","filed_date":"2020-11-16","accession":"0001493152-20-021764","full_text":"https://origin.rootz.global/static/filing/0001493152-20-021764.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":48,"match_count":6,"context":"the value of our common stock as well as a perceived higher value of Gel-Del based on additional patents granted for Gel-Del technology. During early 2017, our management and Gel-Del management again entered into a definitive agreement to effect a merger to replace the abandoned merger, provided we issue an additional 31.3% of our common stock to Gel-Del shareholders than was required by our abandoned merger. This 2017 merger agree","filed_date":"2018-04-27","accession":"0001493152-18-005849","full_text":"https://origin.rootz.global/static/filing/0001493152-18-005849.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":48,"match_count":6,"context":"ating to occupational health and safety and the environment, except for instances of noncompliance that, individually and in the aggregate, have not had and would not reasonably be expected to have a material adverse effect on Gel-Del. Section 2.13. Brokers. No broker, investment banker, financial advisor or other person is entitled to any brokers, finders, financial advisors or other similar fee or commission in connec","filed_date":"2017-03-27","accession":"0001477932-17-001297","full_text":"https://origin.rootz.global/static/filing/0001477932-17-001297.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":48,"match_count":1,"context":"ppoint the president of Social Geek Media, Patrick Aub, as chief executive officer of the Corporation. According, the current Chief Executive Officer Ghislaine St-Hilaire will no longer be CEO but be appointed Executive Vice President. The change in CEO is related to the licensing agreement signed with Social Geed Media which is described in Note 4. The Company wasformed to sell their touch screen product called the Infoscan to ph","filed_date":"2014-02-18","accession":"0001477932-14-000709","full_text":"https://origin.rootz.global/static/filing/0001477932-14-000709.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PETV","company":"PetVivo Holdings, Inc.","exchange":"OTC","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":47,"match_count":4,"context":"and sale of medical devices are subject to future change. We cannot predict what impact, if any, those changes might have on our business. Failure to comply with regulatory requirements could have a material adverse effect on our business, financial condition and results of operations. Pertaining to our Kush device (offered for veterinary use only), in the U.S., the FDA does not require submission of a 510(k), PMA, or","filed_date":"2020-06-29","accession":"0001493152-20-012125","full_text":"https://origin.rootz.global/static/filing/0001493152-20-012125.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"d8438396f4bac27c83a7e8f52da879f9faa23626b196c654b4ddb13fcb605765","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"530b68e7dcb6c5609496265c570ec561fc4c076b2a8304a9d14d2b8c4bb5d04d","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":10,"hourly_limit":500,"remaining":490,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}